Sodium-glucose cotransporter 2 (SGLT2) inhibitors represent a new class of oral antidiabetic drugs that lower blood glucose concentrations in an insulin-independent manner by increasing urinary glucose excretion. Ipragliflozin was the SGLT2 inhibitor to be approved in Korea for the treatment of type 2 diabetes mellitus as monotherapy or in combination with other antidiabetic drugs. Several randomized placebo-controlled studies in Japanese patients with type 2 diabetes mellitus have demonstrated that ipragliflozin was effective in terms of improving glycemic control over 12~52 weeks. In these studies, ipragliflozin was associated with a favorable safety profile, with low rates of mild-to-moderate treatment-emergent adverse events (TEAEs) including genital infection and hypoglycemia. Korea and Japan is an aging society with more than 25% of its population aged ≥ 65 years; moreover, many patients with type 2 diabetes mellitus are of an advanced age. Because the prior studies enrolled relatively few elderly patients and because of the increased risk of comorbidities or TEAEs in elderly patients, it is important to confirm the safety of ipragliflozin in this patient population. I’ll discuss with update on the safety of SGLT-2 inhibitor(ipragliflozin) in elderly Type 2 diabetes patients; focusing on ipragliflozin’s final analysis of STELLA-ELDER